1,510
Participants
Start Date
July 31, 2025
Primary Completion Date
August 31, 2028
Study Completion Date
August 31, 2029
dihydroartemisinin-piperaquine (DP)
Weight-based dosing of 3 (\<60kg), 4 (6-80kg) or 5 (\>80 kg) 40/320 mg tablets of dihydroartemisinin-piperaquine given once daily for 3 days
Pyronaridine-artesunate (PA)
Weight-based dosing of 2 (24-\<45 kg), 3 (45-\<65kg), or 4 (\>=65 kg) 180/60 mg tablets of pyronaridine-artesunate, once daily for 3 days.
Artemether-lumefantrine
1 x 80/480 or 4 x 20/120 mg tablets of artemether-lumefantrine, given twice daily, approximately 8 hours apart for 3 days
Malaria Research and Training Center, University of Sciences, Techniques, and Technologies of Bamako (USTTB),, Bamako
KEMRI Centre for Global Health Research (CGHR), Kisumu
Clinical Research Unit of Nanoro (CRUN), Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest (IRSS-DRO), Nanoro
Malaria Research and Training Center, Mali International Center of Excellence in Research, University of Sciences, Techniques, and Technologies of Bamako, Mali
UNKNOWN
KEMRI Centre for Global Health Research (CGHR), Kisumu, Kenya
UNKNOWN
Clinical Research Unit of Nanoro (CRUN), Institut de Recherche en Sciences de la Santé
UNKNOWN
Medicines for Malaria Venture (co-sponsor)
UNKNOWN
US Centers for Disease Control and Prevention (CDC), Division of Parasitic Diseases & Malaria
UNKNOWN
Liverpool School of Tropical Medicine
OTHER